Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents

od Moxley, Katherine M., McMeekin, D. Scott
Izdano 2010

Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P

od Dizon, Don S., Blessing, John A., McMeekin, D. Scott, Sharma, Sudarshan K., DiSilvestro, Paul, Alvarez, Ronald D.
Izdano 2009

A PHASE II TRIAL OF THALIDOMIDE IN PATIENTS WITH REFRACTORY ENDOMETRIAL CANCER AND CORRELATION WITH ANGIOGENESIS BIOMARKERS: A GYNECOLOGIC ONCOLOGY GROUP STUDY

od McMeekin, D. Scott, Sill, Michael W., Benbrook, Doris, Darcy, Kathleen M., Stearns-Kurosawa, Deborah J., Eaton, Lynne, Yamada, S. Diane
Izdano 2007

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

od Krasner, C N, McMeekin, D S, Chan, S, Braly, P S, Renshaw, F G, Kaye, S, Provencher, D M, Campos, S, Gore, M E
Izdano 2007

A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel) in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal...

od Coleman, Robert L., Brady, William E., McMeekin, D. Scott, Rose, Peter G., Soper, John T., Lentz, Samuel S., Hoffman, James S., Shahin, Mark S.
Izdano 2011

Necessity of Radical Hysterectomy for Endometrial Cancer Patients with Cervical Invasion

od Lee, Taek Sang, Kim, Jae Weon, Kim, Dae Yeon, Kim, Young Tae, Lee, Ki Heon, Kim, Byoung Gie, McMeekin, D. Scott
Izdano 2010

Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study

od Monk, Bradley J., Sill, Michael W., McMeekin, D. Scott, Cohn, David E., Ramondetta, Lois M., Boardman, Cecelia H., Benda, Jo, Cella, David
Izdano 2009

A Phase I Study of Concurrent Weekly Topotecan and Cisplatin Chemotherapy with Whole Pelvic Radiation Therapy in Locally Advanced Cervical Cancer: a Gynecologic Oncology Group Stud...

od Rose, Peter G., Sill, Michael W., McMeekin, D. Scott, Ahmed, Amina, Salani, Ritu, Yamada, S. Diane, Wolfson, Aaron, Fusco, Nancy, Fracasso, Paula M.
izdano v Gynecol Oncol (2011)

Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: A Gynecologic Onco...

od Cella, David, Huang, Helen Q., Monk, Bradley J., Wenzel, Lari, Benda, Jo, McMeekin, D. Scott, Cohn, David, Ramondetta, Lois, Boardman, Cecelia H.
izdano v Gynecol Oncol (2010)

A phase II evaluation of Irofulven (IND#55804, NSC#683863) as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cance...

od Schilder, Russell J., Blessing, John A., Shahin, Mark S., Miller, David S, Tewari, Krishnansu Sujata, Muller, Carolyn Y., Warshal, David, McMeekin, D. Scott, Rotmensch, Jacob
Izdano 2010

Phase II trial of Cetuximab in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

od Santin, Alessandro D., Sill, Michael W., McMeekin, D. Scott, Leitao, Mario M., Brown, Jubilee, Sutton, Gregory P., Van Le, Linda, Griffin, Patricia, Boardman, Cecelia H.
Izdano 2011

A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG...

od McMeekin, D Scott, Sill, Michael W, Walker, Joan L, Moore, Kathleen N, Waggoner, Steven E, Thaker, Premal H, Rizack, Tina, Hoffman, James S, Fracasso, Paula M
izdano v Gynecol Oncol (2015)

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

od Aghajanian, Carol, Sill, Michael W., Darcy, Kathleen M., Greer, Benjamin, McMeekin, D. Scott, Rose, Peter G., Rotmensch, Jacob, Barnes, Mack N., Hanjani, Parviz, Leslie, Kimberly K.
Izdano 2011

Ultra-early Predictive Assay for Treatment Failure Using Functional Magnetic Resonance Imaging and Clinical Prognostic Parameters in Cervical Cancer

od Mayr, Nina A., Yuh, William T. C., Jajoura, David, Wang, Jian Z., Lo, Simon S., Montebello, Joseph F., Porter, Kyle, Zhang, Dongqing, McMeekin, D. Scott, Buatti, John M.
izdano v Cancer (2010)

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

od Moore, Richard G., McMeekin, D. Scott, Brown, Amy K., DiSilvestro, Paul, Miller, M. Craig, Allard, W. Jeffrey, Gajewski, Walter, Kurman, Robert, Bast, Robert C., Skates, Steven J.
Izdano 2008

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial

od Colombo, N, McMeekin, D S, Schwartz, P E, Sessa, C, Gehrig, P A, Holloway, R, Braly, P, Matei, D, Morosky, A, Dodion, P F, Einstein, M H, Haluska, F
Izdano 2013

Etiologic Heterogeneity in Endometrial Cancer: Evidence from a Gynecologic Oncology Group Trial

od Brinton, Louise A., Felix, Ashley S., McMeekin, D. Scott, Creasman, William T., Sherman, Mark E., Mutch, David, Cohn, David E., Walker, Joan L., Moore, Richard G., Downs, Levi S., Soslow, Robert A., Zaino, Richard
Izdano 2013

Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial

od Felix, Ashley S., Brinton, Louise A., McMeekin, D. Scott, Creasman, William T., Mutch, David, Cohn, David E., Walker, Joan L., Moore, Richard G., Downs, Levi S., Soslow, Robert A., Zaino, Richard, Sherman, Mark E.
izdano v J Natl Cancer Inst (2015)

A Phase 1b Dose Escalation Study of Ipafricept (OMP-54F28) in Combination with Paclitaxel and Carboplatin in Patients with Recurrent Platinum-Sensitive Ovarian Cancer

od Moore, Kathleen N., Gunderson, Camille, Sabbatini, Paul, McMeekin, D. Scott, Mantia-Smaldone, Gina, Burger, Robert, Morgan, Mark A., Kapoun, Ann M., Brachmann, Rainer Karl, Stagg, Robert, Farooki, Azeez, O’Cearbhaill, Roisin E
izdano v Gynecol Oncol (2019)

Phase II Trial of Trastuzumab in Women with Advanced or Recurrent, HER2-Positive Endometrial Carcinoma: a Gynecologic Oncology Group Study

od Fleming, Gini F., Sill, Michael W., Darcy, Kathleen M., McMeekin, D. Scott, Thigpen, J. Tate, Adler, Lisa M., Berek, Jonathan S., Chapman, Julia A., DiSilvestro, Paul A., Horowitz, Ira R., Fiorica, James V.
Izdano 2009